Temporal profile of specific antibody against SARS-CoV-2 among infected people: a literature study

WU Wen; ZHOU Gui-xiang; SHI Chao

doi:10.11847/zgggws1136686

Volume 38 Issue 6

Jun. 2022

Turn off MathJax

Article Contents

Article Navigation > Chinese Journal of Public Health > 2022 > 38(6): 804-807

WU Wen, ZHOU Gui-xiang, SHI Chao, . Temporal profile of specific antibody against SARS-CoV-2 among infected people: a literature study[J]. Chinese Journal of Public Health, 2022, 38(6): 804-807. doi: 10.11847/zgggws1136686

Citation:

WU Wen, ZHOU Gui-xiang, SHI Chao, . Temporal profile of specific antibody against SARS-CoV-2 among infected people: a literature study[J]. Chinese Journal of Public Health, 2022, 38(6): 804-807. doi: 10.11847/zgggws1136686

Citation:

PDF( 615 KB)

Temporal profile of specific antibody against SARS-CoV-2 among infected people: a literature study

doi: 10.11847/zgggws1136686

1.
School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province 211100, China

Received Date: 2021-08-27
Available Online: 2021-12-30
Publish Date: 2022-06-01

Abstract

Abstract

Objective To describe the occurrence and dynamic changes of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in infected people. Methods Relevant studies published up to July 2021 were retrieved through systematically searching on PubMed, China National Knowledge Infrastructure (CNKI), and Wanfang Database. Excle 2016 and SPSS 25.0 were used in data collection and analysis. Results From the onset of coronavirus disease 2019 (COVID-19) symptoms, the median time of seroconversion was 8 days (the minimum – the maximum: 1 – 28 days) for immunoglobulin M (IgM), 10 days (0 – 29 days) for IgG, 7 days (1 – 13 days) for IgA, and 9 days (1 – 25.5 days) for neutralizing antibody; the median time of peak antibody titer was 16.5 days (10 – 30 days) for IgM, 21 days (15 – 30 days) for IgG, 21 days (15 – 30 days) for IgA, and 24 days (10 – 45 days) for neutralizing antibody; and the median persistent time of antibody was 63 days (60 – 84 days) for IgM, 105 days (42 – 365 days) for IgG, 41 days (30 – 100 days) for IgA, and 101 days (65 – 270 days) for neutralizing antibody, respectively. Conclusion Among seroconversions of specific antibodies against SARS-CoV-2 in infected persons, IgA occurred first but with the shortest persistent duration, while IgG occurred latest but with the longest persistent duration; the serum titer of IgM peaked first, but that of neutralizing antibody the latest. The duration of serum IgM positive of patients with SARS-CoV-2 infection was shorter than that of patients with SARS-CoV infection. Meanwhile, the durations of serum positive for IgG and neutralizing antibody in SARS-CoV-2 infected patients were shorter than those in the patients with SARS-CoV or Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
- COVID-19,
- specific antibody,
- neutralizing antibody,
- temporal profile

FullText(HTML)

References(35)

References

[1]	Word Health Organization. Coronavirus (COVID-19) data The latest data on the COVID-19 global outbreak[EB/OL]. [2021 – 06 – 13]. https://www.who.int/data#reports.
[2]	Lei Q, Li Y, Hou HY, et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections[J]. Allergy, 2021, 76(2): 551 – 561. doi: 10.1111/all.14622
[3]	Shen L, Wang CH, Zhao JZ, et al. Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression[J]. Emerging Microbes and Infections, 2020, 9(1): 1096 – 1101. doi: 10.1080/22221751.2020.1766382
[4]	Tan WT, Lu YQ, Zhang J, et al. Viral kinetics and antibody responses in patients with COVID-19[J]. medRxiv, 2020, 24(3): 20042382. doi: 10.1101/2020.03.24.20042382.
[5]	Guo L, Ren LL, Yang SY, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)[J]. Clinical Infectious Diseases, 2020, 71(15): 778 – 785. doi: 10.1093/cid/ciaa310
[6]	Xiang F, Wang XR, He XL, et al. Antibody detection and dynamic characteristics in patients with coronavirus disease 2019[J]. Clinical Infectious Diseases, 2020, 71(8): 1930 – 1934. doi: 10.1093/cid/ciaa461
[7]	Pan YB, Li XR, Yang G, et al. Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients[J]. Journal of Infection, 2020, 81(1): e28 – e32. doi: 10.1016/j.jinf.2020.03.051
[8]	Ng DL, Goldgof GM, Shy BR, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood[J]. Nature Communications, 2020, 11(1): 4698. doi: 10.1038/s41467-020-18468-8
[9]	Yu HQ, Sun BQ, Fang ZF, et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients[J]. European Respiratory Journal, 2020, 56(2): 2001526. doi: 10.1183/13993003.01526-2020
[10]	Lou B, Li TD, Zheng SF, et al. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset[J]. European Respiratory Journal, 2020, 56(2): 2000763. doi: 10.1183/13993003.00763-2020
[11]	Wang YQ, Zhang L, Sang L, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity[J]. The Journal of Clinical Investigation, 2020, 130(10): 5235 – 5244. doi: 10.1172/JCI138759
[12]	Padoan A, Sciacovelli L, Basso D, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study[J]. Clinica Chimica Acta, 2020, 507: 164 – 166. doi: 10.1016/j.cca.2020.04.026
[13]	Zeng WH, Ma H, Ding CC, et al. Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA[J]. Signal Transduction and Targeted Therapy, 2021, 6(1): 35. doi: 10.1038/s41392-021-00478-7
[14]	Isho B, Abe KT, Zuo M, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients[J]. Science Immunology, 2020, 5(52): eabe5511. doi: 10.1126/sciimmunol.abe5511
[15]	Seow J, Graham C, Merrick B, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection[J]. medRxiv, 2020, 9(7): 20148429. doi: 10.1101/2020.07.09.20148429.
[16]	Zhang XY, Lu SW, Li H, et al. Viral and antibody kinetics of COVID-19 patients with different disease severities in acute and convalescent phases: a 6-month follow-up study[J]. Virologica Sinica, 2020, 35(6): 820 – 829. doi: 10.1007/s12250-020-00329-9
[17]	Wu J, Liang BY, Chen CR, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19[J]. Nature Communications, 2021, 12(1): 1813. doi: 10.1038/s41467-021-22034-1
[18]	Kulkarni R, Patil HP, Palkar S, et al. Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β-propiolactone-inactivated, whole virus-based indirect ELISA[J]. Journal of Virological Methods, 2021, 287: 113996. doi: 10.1016/j.jviromet.2020.113996
[19]	Cervia C, Nilsson J, Zurbuchen Y, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19[J]. The Journal of Allergy and Clinical Immunology, 2021, 147(2): 545 – 557.e9. doi: 10.1016/j.jaci.2020.10.040
[20]	Caturegli G, Materi J, Howard BM, et al. Clinical validity of serum antibodies to SARS-CoV-2: a case-control study[J]. Annals of Internal Medicine, 2020, 173(8): 614 – 622. doi: 10.7326/M20-2889
[21]	Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19[J]. Nature Medicine, 2020, 26(6): 845 – 848. doi: 10.1038/s41591-020-0897-1
[22]	Li CS, Yu D, Wu X, et al. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan[J]. Nature Communications, 2021, 12(1): 4144. doi: 10.1038/s41467-021-24230-5
[23]	Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity[J]. Immunity, 2020, 53(5): 925 – 933.e4. doi: 10.1016/j.immuni.2020.10.004
[24]	Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2[J]. Science Translational Medicine, 2021, 13(577): eabd2223. doi: 10.1126/scitranslmed.abd2223
[25]	Jiang XL, Wang GL, Zhao XN, et al. Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection[J]. Nature Communications, 2021, 12(1): 897. doi: 10.1038/s41467-021-21155-x
[26]	Wu F, Wang AJ, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications[J]. medRxiv, 2020, 30(3): 20047365. doi: 10.2139/ssrn.3566211.
[27]	Grzelak L, Temmam S, Planchais C, et al. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations[J]. Science Translational Medicine, 2020, 12(559): eabc3103. doi: 10.1126/scitranslmed.abc3103
[28]	He ZY, Ren LL, Yang JT, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study[J]. The Lancet, 2021, 397(10279): 1075 – 1084. doi: 10.1016/S0140-6736(21)00238-5
[29]	Sinderewicz E, Czelejewska W, Jezierska-Wozniak K, et al. Immune response to COVID-19: can we benefit from the SARS-CoV and MERS-CoV pandemic experience?[J]. Pathogens, 2020, 9(9): 739. doi: 10.3390/pathogens9090739
[30]	Guo XQ, Guo ZM, Duan CH, et al. Long-term persistence of IgG antibodies in SARS-CoV infected healthcare workers[J]. medRxiv, 2020, 12(2): 20021386. doi: 10.1101/2020.02.12.20021386.
[31]	Alshukairi AN, Zhao JC, Al-Mozaini MA, et al. Longevity of middle east respiratory syndrome coronavirus antibody responses in Humans, Saudi Arabia[J]. Emerging Infectious Diseases, 2021, 27(5): 1472 – 1476.
[32]	Cao WC, Liu W, Zhang PH, et al. Disappearance of antibodies to SARS-associated coronavirus after recovery[J]. The New England Journal of Medicine, 2007, 357(11): 1162 – 1163. doi: 10.1056/NEJMc070348
[33]	Li G, Chen XJ, Xu AL. Profile of specific antibodies to the SARS-associated coronavirus[J]. The New England Journal of Medicine, 2003, 349(5): 508 – 509. doi: 10.1056/NEJM200307313490520
[34]	孙永, 何军, 蔡芬, 等. 新型冠状病毒IgG/IgM抗体双重检测免疫层析方法的建立研究[J]. 合肥工业大学学报: 自然科学版, 2020, 43(5): 700 – 705.
[35]	崔小平, 崔犇, 杜红心, 等. 新型冠状病毒IgM和IgG抗体检测对新冠肺炎的诊断效能评价[J]. 现代医药卫生, 2020, 36(19): 3015 – 3017. doi: 10.3969/j.issn.1009-5519.2020.19.003